Literature DB >> 26559559

Dabigatran in 'real-world' clinical practice for stroke prevention in patients with non-valvular atrial fibrillation.

Tatjana S Potpara1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26559559     DOI： 10.1160/TH15-10-0825

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  9 in total

1.  Claims Data Studies of Direct Oral Anticoagulants Can Achieve Balance in Important Clinical Parameters Only Observable in Electronic Health Records.

Authors:  Krista F Huybrechts; Chandrasekar Gopalakrishnan; Jessica M Franklin; Kristina Zint; Lionel Riou Franca; Dorothee B Bartels; Joan Landon; Sebastian Schneeweiss
Journal:  Clin Pharmacol Ther       Date:  2018-11-11       Impact factor: 6.875

Review 2.  Management of atrial high-rate episodes detected by cardiac implanted electronic devices.

Authors:  Ben Freedman; Giuseppe Boriani; Taya V Glotzer; Jeff S Healey; Paulus Kirchhof; Tatjana S Potpara
Journal:  Nat Rev Cardiol       Date:  2017-07-06       Impact factor: 32.419

3.  Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.

Authors:  Xiaoxi Yao; Neena S Abraham; Lindsey R Sangaralingham; M Fernanda Bellolio; Robert D McBane; Nilay D Shah; Peter A Noseworthy
Journal:  J Am Heart Assoc       Date:  2016-06-13       Impact factor: 5.501

Review 4.  DOACs - advances and limitations in real world.

Authors:  Lai Heng Lee
Journal:  Thromb J       Date:  2016-10-04

Review 5.  Recent advances in the understanding and management of atrial fibrillation: a focus on stroke prevention.

Authors:  Farhan Shahid; Eduard Shantsila; Gregory Y H Lip
Journal:  F1000Res       Date:  2016-12-20

6.  The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey.

Authors:  Tatjana S Potpara; Elina Trendafilova; Gheorghe-Andrei Dan; Artan Goda; Zumreta Kusljugic; Sime Manola; Ljilja Music; Viktor Gjini; Belma Pojskic; Mircea Ioakim Popescu; Catalina Arsenescu Georgescu; Elena S Dimitrova; Delyana Kamenova; Uliks Ekmeciu; Denis Mrsic; Ana Nenezic; Sandro Brusich; Srdjan Milanov; Ivan Zeljkovic; Gregory Y H Lip
Journal:  Adv Ther       Date:  2017-08-09       Impact factor: 3.845

Review 7.  Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor.

Authors:  Tatjana S Potpara; Nikolaos Dagres; Nebojša Mujović; Dragan Vasić; Milika Ašanin; Milan Nedeljkovic; Francisco Marin; Laurent Fauchier; Carina Blomstrom-Lundqvist; Gregory Y H Lip
Journal:  Adv Ther       Date:  2016-12-08       Impact factor: 3.845

Review 8.  Pharmacological and Non-pharmacological Treatments for Stroke Prevention in Patients with Atrial Fibrillation.

Authors:  Laura Ueberham; Nikolaos Dagres; Tatjana S Potpara; Andreas Bollmann; Gerhard Hindricks
Journal:  Adv Ther       Date:  2017-09-27       Impact factor: 3.845

Review 9.  Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants.

Authors:  Natalia Cullell; Caty Carrera; Elena Muiño; Nuria Torres; Jerzy Krupinski; Israel Fernandez-Cadenas
Journal:  Oncotarget       Date:  2018-06-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.